Latent Tuberculosis Infection Management in Solid Organ Transplantation Recipients: A National Snapshot

ÖZGEN ALPAYDIN A., Turunç T. Y., AVKAN OĞUZ V., Öner-Eyüboğlu F., Tükenmez-Tigen E., HASANOĞLU İ., ...More

Thoracic Research and Practice, vol.25, no.3, pp.130-135, 2024 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 3
  • Publication Date: 2024
  • Doi Number: 10.5152/thoracrespract.2024.23110
  • Journal Name: Thoracic Research and Practice
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.130-135
  • Keywords: interferon-gamma release test, latent tuberculosis infection, Solid organ transplantation, tuberculin skin test, tuberculosis
  • Dokuz Eylül University Affiliated: Yes


OBJECTIVE: Latent tuberculosis infection (LTBI) screening is strongly recommended in the pre-transplant evaluation of solid organ transplant (SOT) recipients, although it remains inadequate in many transplant centers. We decided to investigate pre-transplant TB risk assessment, LTBI treatment, and registry rates in Türkiye. MATERIAL AND METHODS: Adult SOT recipients who underwent tuberculin skin test (TST) and/or interferon-gamma release test (IGRA) from 14 centers between 2015 and 2019 were included in the study. An induration of ≥5 mm on TST and/or probable/positive IGRA (QuantiFERON-TB) was considered positive for LTBI. Demographic features, LTBI screening and treatment, and pre-/post-transplant TB history were recorded from the electronic database of transplantation units across the country and pooled at a single center for a unified database. RESULTS: TST and/or IGRA were performed in 766 (33.8%) of 2266 screened patients most of whom were kidney transplant recipients (n = 485, 63.4%). LTBI screening test was positive in 359 (46.9%) patients, and isoniazid was given to 203 (56.5%) patients. Of the patients treated for LTBI, 112 (55.2%) were registered in the national registry, and 82 (73.2%) completed the treatment. Tuberculosis developed in 6 (1.06%) of 563 patients who were not offered LTBI treatment. CONCLUSION: We determined that overall, only one-third of SOT recipients in our country were evaluated in terms of TB risk, only 1 of the 2 SOT recipients with LTBI received treatment, and half were registered. Therefore, we want to emphasize the critical importance of pre-transplant TB risk stratification and registration, guided by revised national guidelines.